AlphaYouRS
Schedule 13D filing
Roivant Sciences Ltd. disclosed a 19.5% stake in Arbutus Biopharma Corp (ABUS)
Roivant Sciences Ltd. reported owning 19.5% of Arbutus Biopharma Corp (ABUS) (29,880,079 shares) in a Schedule 13D filed Oct 6, 2026.
A 13D means the holder may push for changes at the company.
- Disclosed
- Oct 6, 2026
- Source
- Schedule 13D
From a public Schedule 13D, linked above. Not investment advice, and not a recommendation to buy or sell.